Brief: China Health Group Says Ritonavir Has Inhibitory Effect & Efficacy Report On Coronavirus
29/01/2020 14:53
Jan 29 (Reuters) - China Health Group Inc 8225.HK :
* CO'S CORONAVIRUS SPECIAL PROJECT GROUP FOUND RITONAVIR HAS
INHIBITORY EFFECT & EFFICACY REPORT ON CORONAVIRUS
* A RELATED CO OF GROUP, IS ONLY DOMESTIC ENTERPRISE THAT
HAS
PRODUCED PREPARATION OF PRODUCT IN HISTORY & HAS RAW MATERIAL
APPROVAL
* WANQUAN WANTE XIAMEN PHARMACEUTICAL APPLIED TO STATE FOOD
AND
DRUG ADMINISTRATION FOR RESUMPTION OF PRODUCTION OF RITONAVIR
Source text for Eikon: ID:nHKS3rvj22
Further company coverage: 8225.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Health
See all newsBrief: China Health Group Says Court Dismisses Application To Set Aside Arbitration Award
Brief: China Health Says China Medical Group Initiated Legal Proceedings
Brief: China Health Group Says Song Xuemei Tendered Resignation As Executive Director
Brief: China Health Group Says Revenue Recognized In 1Q22 & 2Q22 Has Been Partially Adjusted During 4Q22
Brief: China Health Group Makes Application To Stock Exchange For Resumption In Trading